Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study
Objective: Evidence on the prognostic value of autologous stem cell transplantation (ASCT) and minimal residual disease (MRD) dynamics of patients with newly diagnosed multiple myeloma (NDMM) in China is limited. Our objective in the current study was to understand the current care paradigm and outc...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2023-01-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/20/1/77 |
| _version_ | 1797951332651368448 |
|---|---|
| author | Huishou Fan Weida Wang Ya Zhang Jianxiang Wang Tao Cheng Lugui Qiu Xin Wang Zhongjun Xia Gang An |
| author_facet | Huishou Fan Weida Wang Ya Zhang Jianxiang Wang Tao Cheng Lugui Qiu Xin Wang Zhongjun Xia Gang An |
| author_sort | Huishou Fan |
| collection | DOAJ |
| description | Objective: Evidence on the prognostic value of autologous stem cell transplantation (ASCT) and minimal residual disease (MRD) dynamics of patients with newly diagnosed multiple myeloma (NDMM) in China is limited. Our objective in the current study was to understand the current care paradigm and outcomes of these patients. Methods: This longitudinal cohort study used historical data from three top-tier hematologic disease care hospitals that contributed to the National Longitudinal Cohort of Hematological Diseases-Multiple Myeloma. Treatment regimens [proteasome inhibitor (PI)-, immunomodulatory drug (IMiD)-, PI+IMiD-based, and conventional], post-induction response, ASCT and MRD status, and survival outcomes [progression-free survival (PFS) and overall survival (OS)] were evaluated. Results: In total, 454 patients with NDMM were included (median age, 57 years; 59.0% males) with a median follow-up of 58.7 months. The overall response rate was 91.0%, 83.9%, 90.6%, and 60.9% for PI-, IMiD-, PI+IMiD-based, and conventional regimens, respectively. Patients with ASCT during first-line therapy (26.2%) had a longer PFS and OS than patients who did not receive ASCT [median PFS, 42.9 vs. 21.2 months, P < 0.001; median OS, not reached (NR) vs. 65.8 months, P < 0.001]. The median OS was NR, 71.5, and 56.6 months among patients with sustained MRD negativity, loss of MRD negativity, and persistent MRD, respectively (P < 0.001). Multivariate analysis revealed that the lactic dehydrogenase level, International Staging System stage, extra-medullary disease, and upfront ASCT were independent factors in predicting OS among NDMM patients. Conclusions: Our study showed that novel agent-based regimens, first-line ASCT, and sustained MRD negativity were associated with a superior outcome for patients with NDMM in China (Identifier: NCT04645199). |
| first_indexed | 2024-04-10T22:28:53Z |
| format | Article |
| id | doaj.art-b47c031a46494d85a985c3e684a2cf5a |
| institution | Directory Open Access Journal |
| issn | 2095-3941 |
| language | English |
| last_indexed | 2024-04-10T22:28:53Z |
| publishDate | 2023-01-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-b47c031a46494d85a985c3e684a2cf5a2023-01-17T07:48:27ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412023-01-01201778710.20892/j.issn.2095-3941.2022.0612Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter studyHuishou Fan0Weida Wang1Ya Zhang2Jianxiang Wang3Tao Cheng4Lugui Qiu5Xin Wang6Zhongjun Xia7Gang An8State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, ChinaState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, ChinaState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, ChinaState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, ChinaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, ChinaState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, ChinaObjective: Evidence on the prognostic value of autologous stem cell transplantation (ASCT) and minimal residual disease (MRD) dynamics of patients with newly diagnosed multiple myeloma (NDMM) in China is limited. Our objective in the current study was to understand the current care paradigm and outcomes of these patients. Methods: This longitudinal cohort study used historical data from three top-tier hematologic disease care hospitals that contributed to the National Longitudinal Cohort of Hematological Diseases-Multiple Myeloma. Treatment regimens [proteasome inhibitor (PI)-, immunomodulatory drug (IMiD)-, PI+IMiD-based, and conventional], post-induction response, ASCT and MRD status, and survival outcomes [progression-free survival (PFS) and overall survival (OS)] were evaluated. Results: In total, 454 patients with NDMM were included (median age, 57 years; 59.0% males) with a median follow-up of 58.7 months. The overall response rate was 91.0%, 83.9%, 90.6%, and 60.9% for PI-, IMiD-, PI+IMiD-based, and conventional regimens, respectively. Patients with ASCT during first-line therapy (26.2%) had a longer PFS and OS than patients who did not receive ASCT [median PFS, 42.9 vs. 21.2 months, P < 0.001; median OS, not reached (NR) vs. 65.8 months, P < 0.001]. The median OS was NR, 71.5, and 56.6 months among patients with sustained MRD negativity, loss of MRD negativity, and persistent MRD, respectively (P < 0.001). Multivariate analysis revealed that the lactic dehydrogenase level, International Staging System stage, extra-medullary disease, and upfront ASCT were independent factors in predicting OS among NDMM patients. Conclusions: Our study showed that novel agent-based regimens, first-line ASCT, and sustained MRD negativity were associated with a superior outcome for patients with NDMM in China (Identifier: NCT04645199).https://www.cancerbiomed.org/content/20/1/77multiple myelomaautologous stem cell transplantationminimal residual diseasesurvival outcomesmulticenter study |
| spellingShingle | Huishou Fan Weida Wang Ya Zhang Jianxiang Wang Tao Cheng Lugui Qiu Xin Wang Zhongjun Xia Gang An Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study Cancer Biology & Medicine multiple myeloma autologous stem cell transplantation minimal residual disease survival outcomes multicenter study |
| title | Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study |
| title_full | Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study |
| title_fullStr | Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study |
| title_full_unstemmed | Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study |
| title_short | Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study |
| title_sort | current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in china a retrospective multicenter study |
| topic | multiple myeloma autologous stem cell transplantation minimal residual disease survival outcomes multicenter study |
| url | https://www.cancerbiomed.org/content/20/1/77 |
| work_keys_str_mv | AT huishoufan currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy AT weidawang currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy AT yazhang currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy AT jianxiangwang currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy AT taocheng currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy AT luguiqiu currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy AT xinwang currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy AT zhongjunxia currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy AT gangan currenttreatmentparadigmandsurvivaloutcomesamongpatientswithnewlydiagnosedmultiplemyelomainchinaaretrospectivemulticenterstudy |